Is the acquisitions part of 'sustaining capex'? That's the key question...what does Mayne have to pay as part of getting more drugs into their portfolio? This is currently categorised as 'acquisitions' but not sustaining capex, but in reality, if they stop the acquisitions, what will happen to their future product portfolio and cashflows?
